Huamei Haolian Medical Technology

The company's core services leverage AI technology and integrated medical resources to offer full-cycle health management, spanning pre-diagnosis, in-diagnosis, and post-diagnosis phases. Huamei Haolian has developed proprietary AI products such as "AI General Practitioner" and "AI Precise Medical Treatment," launched in 2022. Its core algorithms for "precise medical treatment" and "TCM inquiries" have received official备案 (bèi àn, record-filing) in the precision medicine field, and its health management large model has completed national-level generative AI service备案, positioning it as a compliant provider of large-scale AI applications.

Huamei Haolian provides a range of services including online consultations, video doctor appointments, green channel access for medical treatment, international multi-disciplinary consultations, and access to specialty drugs. As of early 2026, the company's network includes over 1,650 Grade-A tertiary hospitals in China and partnerships with more than 300 domestic medical institutions. It also has links to 8 international medical systems and nearly 3,000 international experts. The firm has served nearly 300 B2B clients and over 56 million end-users.

The company has secured significant funding through multiple rounds. A Series C round in July 2024 raised nearly 100 million yuan from investors including Amiba Capital, Ventech China, and Fengqiao Capital. This was followed by a Series D round of several hundred million yuan in March 2026, co-led by Yifeng Capital, YHLO, Ventech China, and Fengqiao Capital, with participation from Oriental Fortune Capital, GSR Ventures, and a Tongji University alumni fund.